ArticleBMC ophthalmology2025
Ptosis: an uncommon manifestation to autoimmune disease activity in systemic lupus erythematosus.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic lupus erythematosus (SLE) is an autoimmune disease with diverse manifestations, including rare neuro-ophthalmic complications. Isolated unilateral ptosis as a presenting sign of SLE is uncommon and diagnostic uncertainty often exists. CASE PRESENTATION: A 30-year-old woman with a 16-year history of SLE presented with acute right-sided ptosis without other neurological deficits while on stable maintenance immunosuppressive therapy. MRI of the brain and orbits, along with other relevant investigations, excluded common structural causes and showed no abnormalities. Serological testing indicated moderately active SLE, supporting an autoimmune flare as the likely mechanism. Myasthenia gravis-specific testing was not performed, a recognized limitation, but was considered clinically unnecessary given the absence of fatigability, diurnal variation, or generalized weakness. The ptosis resolved completely within 24 h of initiating high-dose systemic corticosteroid therapy.
conclusionsIsolated unilateral ptosis may represent a rare neuro-ophthalmic manifestation of SLE, though alternative diagnoses cannot be definitively excluded. The rapid steroid response may suggest an inflammatory or autoimmune mechanism, underscoring the importance of considering such etiologies and initiating timely immunosuppressive therapy when appropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.